RVU120(SEL120)

TERMINATED · PHASE1 · Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome

RPD2 has been identified

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.